Background There are limited long‐term,'real‐world'data on ustekinumab, or the effect of
dose adjustment in suboptimal responders. Objectives We describe 52‐week data from …

Background Limited data exist on transitioning patients with psoriasis from conventional
systemic agents to biologics. Objectives The TRANSIT study aimed to assess the efficacy …

Background Evaluation of the dosing flexibility and long‐term efficacy of biological agents is
limited. Objectives To evaluate the long‐term efficacy and safety of ustekinumab with and …

Background: Efficacy and safety profiles of ustekinumab have been proved in numerous
clinical trials. However, relevant variations with daily practice have been shown and few …

Background Phase III studies showed that some patients maintained response for≥ 6
months following ustekinumab discontinuation. Objectives To assess clinical responses with …

Background An unmet need remains for safe and effective long‐term treatments of psoriasis.
Objectives To evaluate ustekinumab efficacy and safety for up to 3 years in the PHOENIX 1 …

Objectives: Ustekinumab is the most recently approved biologic for the treatment of
moderate-to-severe psoriasis. Real-world dosing patterns of ustekinumab are yet to be fully …

Background Psoriasis is a chronic, recurrent skin disease that affects approximately 2–3% of
the world's population, and can significantly impair patients' wellbeing and their physical and …

BACKGROUND: Ustekinumab targets interleukin (IL)-12 and IL-23 in the treatment of
moderate-to-severe psoriasis. OBJECTIVE: To evaluate overall pooled study data to assess …

Background: Limited information is available from real-life studies evaluating the long-term
efficacy and drug retention of ustekinumab. Research design and methods: Data from 378 …